The firm that birthed Moderna unveils new startup for next play in RNA
Incubated by Flagship Pioneering, biotech firm Laronde is developing endless RNA, or eRNA, a new class of medicines that goes beyond messenger RNA-based therapies. Flagship is backing the startup $50 million in Series A financing.